Follow the Money: International Expansion for Cell Therapies, BPZE1 Pertussis Vaccine, Next-Gen AI De Novo Antibody Design

$257M: Series D for Global Cell Therapy Manufacturing 

Cellares announced a $257 million Series D financing. The round will fund the global buildout of automated IDMO Smart Factories across South San Francisco; Bridgewater, New Jersey; Leiden, the Netherlands; and Kashiwa City, Japan, to enable commercial launch and unconstrained manufacturing of cell therapies for hundreds of thousands of patients annually. Cellares’ IDMO model replaces manual labor‑intensive contract manufacturing with the most advanced technologies for manufacturing and quality control—fully automated, GMP-compliant, and ready for clinical and commercial use.

$130M: Series D for Musculoskeletal Disease Therapies 

Angitia Biopharmaceuticals closed a $130 million Series D financing round. Proceeds will support the ongoing clinical development of AGA2118, AGA2115, AGA111, and other pipeline assets. AGA2118, AGA2115, and AGA111 are biologic product candidates for the treatment of postmenopausal osteoporosis, osteogenesis imperfecta, and spinal fusion. 

$115M: Series B for the Pertussis Vaccine 

ILiAD Biotechnologies announced the successful closing of an oversubscribed $115 million Series B financing. Proceeds will support the advancement of ILiAD’s next generation pertussis vaccine candidate, BPZE1. Inducing both systemic and mucosal immunity, BPZE1 is a live attenuated intranasal pertussis vaccine designed to provide durable and comprehensive immunity for the prevention of B. pertussis infection, disease (whooping cough), and transmission. The company expects to begin a pivotal human challenge trial of BPZE1 in 2026, with initial data expected in 2027.

$96M: Financing for Personalized Immunotherapy for Colorectal Cancer 

Neogap Therapeutics has raised $96 million in a financing round. The funds will be used to advance the company’s ongoing clinical study and to build the data required for the next stage of Neogap’s development program. The ongoing clinical study is a first-in-human trial evaluating Neogap’s personalized cell therapy in patients with advanced colorectal cancer. The primary focus is on safety and tolerability, while the study also generates early clinical and exploratory data. Several patients have been treated and previously communicated safety data indicate that the treatment is well tolerated.

$85M: Series B for Oral Therapies for Immunology and Inflammation 

QuantX Biosciences announced the closing of an oversubscribed $85 million Series B financing. The funds will be used to support the clinical development of its best-in-class STAT6 oral small molecule inhibitor and IL-17 oral small molecule inhibitor, in addition to continued discovery efforts for oral therapies in immunology and inflammation. 

$60M: Series A for Molecular Glue, Small Molecules  

Breakthru Medicine emerged from stealth with a $60 million Series A financing round following a prior undisclosed seed round. The company chose not to publicly disclose details on their emerging molecular glue platform or their pipeline in small molecules and novel antibody-drug conjugate payloads. They focus on targeted therapy areas that affect many cancer patients, where existing approaches have had limited success.  

$52.5M: Series A for AI Clinical Trial Program 

Biorce has secured $52.5m through a Series A funding round to support the global rollout of its AI clinical trial program. Aika, Biorce’s clinical trial platform, is designed to optimize trial design and operations, allowing study operators to create “regulator-ready protocols” in 90 seconds with 86% accuracy. Built on a data pool of over one million clinical trials, the disease-agnostic technology functions through a multi-modality approach.

$52M: Series A for Oncology, Immunology, and Inflammation Portfolio 

Third Arc Bio has closed a $52 million Series A extension. Proceeds will enable Third Arc Bio to accelerate its immunology and inflammation portfolio and deliver additional oncology programs into the clinic. Since its launch in 2022, Third Arc Bio has assembled a highly experienced team, an innovative platform, and a pipeline of multispecific antibodies. The company's lead asset ARC101 is a bispecific T cell engager targeting CLDN6 currently in phase 1 dose escalation in patients with advanced solid tumors. 

$47M: Series B for Next-Gen AI for De Novo Antibody Design 

Galux announced the successful completion of a $29 million Series B financing. This brings the company’s total raised capital to $47 million. This funding will be used to accelerate the development of next-generation AI that goes beyond binder design to incorporate functional activity and developability, enabling the creation of more robust and therapeutically viable molecules. Galux’s GaluxDesign specializes in de novo antibody design. It successfully generated high-affinity antibodies against a range of therapeutic targets and confirmed that its AI-designed antibody structure was highly consistent with the cryo-EM experimental structure, demonstrating both the precision and generalizability of the platform.

$45M: Series C for Operating System for AI-Ready Labs 

Automata closed a $45 million Series C funding round to address manual, fragmented lab workflows. Automata aims to solve this disconnect by building the reference architecture for autonomous wet labs—combining modular robotics, orchestration software, and unified data infrastructure to transform physical labs into programmable, repeatable, AI-ready systems. The proceeds will be used to scale customer deployments, build the next iteration of the company’s data and closed-loop experimentation software platform, and expand global operations. 

$39M: Series A for RNAi Interference Therapeutics 

Aerska announced the closing of a $39 million Series A financing. The funding will be used to advance its brain shuttle technology to improve delivery of RNAi interference (RNAi) therapeutics across the blood-brain barrier for treating neurological diseases. Aerska’s AOC platform is pioneering systemically delivered RNA medicines capable of reaching the brain to treat neurological diseases at their source. The platform uses proprietary “brain shuttle” technology to overcome the blood-brain barrier, a fundamental challenge that has historically limited RNA therapeutics in CNS diseases. This delivery approach is designed to enable intravenous or subcutaneous administration, achieving uniform and deep brain distribution with durable target gene knockdown, unlocking new therapeutic possibilities for neurological diseases.

$23.3M: Series B for GPCR-targeting Therapies 

Kainova Therapeutics announced the successful first close of its Series B financing round totaling $23.3 million. The proceeds will support the clinical advancement of the company’s GPCR-targeting therapies. Lead asset DT-7012, a Treg-depleting anti-CCR8 antibody, is progressing in the ongoing phase 1/2 DOMISOL trial for the treatment of solid tumors. The company is also advancing other GPCR-targeting therapies, including DT-9081, an EP4 antagonist for solid tumors and DT-9046, a small molecule biased antagonist of PAR2 for inflammatory conditions.

$23.3M: Series B for Solid Tumor Immunotherapy 

Primmune Therapeutics closed an additional $8.6 million to its Series B financing round, totaling $23.3 million. These funds will be used to support the further clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll-like receptor 7 (TLR7) agonist as an immunotherapy for solid tumors. Primmune Therapeutics will initiate Study PRTX007-003, a phase 2 neoadjuvant efficacy study using PRTX007 in combination with standard-of-care anti-PD-1 therapy in patients with Stage III resectable melanoma. 

$18M: Series B for Programmable Tissue Regenerative Therapies 

Pandorum Technologies closed an $18 million Series B financing round to advance the clinical development of its disease-modifying, tunable, exosome-based therapies, including Kuragenx, while scaling global manufacturing and expanding operations across the U.S., Japan, and the Middle East. 

$17M: Series A for Regenerative Medicine 

PranaX Corporation announced the closing of its oversubscribed $17 million Series A financing. Proceeds will be used to advance PranaX's research and development initiatives, expand scientific and operational infrastructure, support strategic partnerships, and accelerate product development and commercialization efforts. As consumer and provider demand shifts toward science-backed, biologically informed solutions that support healthy aging and overall quality of life, exosomes are increasingly viewed as a foundational component of next-generation regenerative strategies. 

$15.5M: Seed Financing for Methyl-Copying PCR Platform 

Syndex Bio successfully closed an oversubscribed $15.5 million seed financing. The funds will support expansion of the mcPCR (methyl-copying PCR) platform, development of clinical workflows and applications, and build‑out of the company's R&D footprint in Cambridge, UK. mcPCR enables ‘PCR for methylation’. By enabling simpler, faster, and more sensitive analysis of methylated DNA, mcPCR will help to transform the testing of clinical samples, especially in non-invasive and small-sample biopsies for early disease detection and recurrence monitoring. 

$3.5M: Seed Financing for Novel Drug Delivery Patch 

ArrayPatch announced the first close of its $3.5 million seed funding round. The new financing will enable ArrayPatch to accelerate the clinical development of ITZ-DerMap, the first product emerging from its proprietary DerMap platform, toward clinical proof-of-concept. DerMap is a pain-free microneedle patch comprising microscopic needles which are uniquely polymer-free and made entirely from the drug being delivered. On application of the patch, the microneedles penetrate the outer layer of skin, dissolve and release medication to the target site.